Association of miRNA-related Genetic Polymorphisms and Prognosis in Patients with Esophageal Squamous Cell Carcinoma

Annals of Surgical Oncology

Volumn 21, Issue 4, 2014, Pages 601-609

  Yang, Pei Wen ^a   Huang, Ya Chuan ^a   Hsieh, Ching Yueh ^a   Hua, Kuo Tai ^a   Huang, Yu Ting ^a   Chiang, Tzu Hsuan ^a   Chen, Jin Shing ^a   Huang, Pei Ming ^a   Hsu, Hsao Hsun ^a   Kuo, Shuenn Wen ^a   Kuo, Min Liang ^a,b   Lee, Jang Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GEMIN4 PROTEIN, HUMAN; MICRORNA; MIRN608 MICRORNA, HUMAN; RAN PROTEIN; RAN PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN;

AGED; CARCINOMA, SQUAMOUS CELL; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; FEMALE; GENETICS; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RAN GTP-BINDING PROTEIN; RETROSPECTIVE STUDIES; RIBONUCLEOPROTEINS, SMALL NUCLEAR; SURVIVAL RATE;

EID: 84939873467     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3709-3     Document Type: Article

References (42)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–907.
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.
4. Islami F, Fedirko V, Tramacere I, et al. Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers: a systematic review and meta-analysis. Int J Cancer. 2011;129:2473–84.
5. Tran GD, Sun XD, Abnet CC, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005;113:456–63.
6. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–7.
7. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161–7.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
9. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11:228–34.
10. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett. 2009;285:116–26.
11. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol. 2007;8:23–36.
12. Murashov AK, Chintalgattu V, Islamov RR, et al. RNAi pathway is functional in peripheral nerve axons. FASEB J. 2007;21:656–70.
13. Mourelatos Z, Dostie J, Paushkin S, et al. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 2002;16:720–8.
14. Huang Y, Yang S, Zhang J, et al. MicroRNAs as promising biomarkers for diagnosing human cancer. Cancer Invest. In press.
15. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem. 2009;55:623–31.
16. Osaki M, Takeshita F, Ochiya T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers. 2008;13:658–70.
17. Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg. 2008;135:255–60.
18. Guo Y, Chen Z, Zhang L, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 2008;68:26–33.
19. Hu Y, Correa AM, Hoque A, et al. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2011;128:132–43.
20. Mathe EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 2009;15:6192–200.
21. Hu Y, Correa AM, Hoque A, et al. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. In press.
22. Mittal GPGaRD. MicroRNAs: potential biomarkers in cancer. Indian J Clin Biochem. 2010;25:4–14.
23. Xu T, Zhu Y, Wei QK, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis. 2008;29:2126–31.
24. Hu Z, Chen J, Tian T, et al. Genetic variants of miRNA sequences and non–small cell lung cancer survival. J Clin Invest. 2008;118:2600–8.
25. Ye Y, Wang KK, Gu J, et al. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila Pa). 2008;1:460–9.
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180–4.
27. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th edition. New York: Springer, 2010. p. 143–59.
28. Sherry ST, Ward M, Sirotkin K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res. 1999;9:677–9.
29. Wu C, Li M, Hu C, Duan H. Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy. Cancer Chemother Pharmacol. In press.
30. Hu W, Chan CS, Wu R, et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell. 2010;38:689–99.
31. Landi D, Gemignani F, Barale R, Landi S. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol. 2008;27:35–43.
32. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis. 2010;31:1805–12.
33. Huang AJ, Yu KD, Li J, Fan L, Shao ZM. Polymorphism rs4919510:C > G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes. PLoS One. 2012;7:e35252.
34. Ryan BM, McClary AC, Valeri N, et al. rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer. PLoS One. 2012;7:e36306.
35. Lin M, Gu J, Eng C, et al. Genetic polymorphisms in microRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res. 2012;18:3982–91.
36. Xing J, Wan S, Zhou F, et al. Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2012;21:217–27.
37. Kang JG, Majerciak V, Uldrick TS, et al. Kaposi’s sarcoma–associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation. J Pathol. 2011;225:378–89.
38. Kang JG, Pripuzova N, Majerciak V, Kruhlak M, Le SY, Zheng ZM. Kaposi’s sarcoma–associated herpesvirus ORF57 promotes escape of viral and human interleukin-6 from microRNA-mediated suppression. J Virol. 2011;85:2620–30.
39. Lukaszewicz-Zajac M, Mroczko B, Kozlowski M, Niklinski J, Laudanski J, Szmitkowski M. Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. Dis Esophagus. In press.
40. Oka M, Yamamoto K, Takahashi M, et al. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. 1996;56:2776–80.
41. Leu CM, Wong FH, Chang C, Huang SF, Hu CP. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene. 2003;22:7809–18.
42. Horikawa Y, Wood CG, Yang H, et al. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res. 2008;14:7956–62.